However, unlike the treatments targeting other gene alterations, such as EGFR mutations in NSCLC (6), targeting KRAS has yet to be successful enough to revolutionize KRAS-mutated cancer treatment. This evidence concerns the gene KRAS and non-small cell lung carcinoma.